Cuba: CITMA awards CIM for effective monoclonal antibody Nimotuzumab

Havana, Jan 11 (Prensa Latina) The Science, Technology and Environment Ministry (CITMA) awarded Cuba's Center for Molecular Immunology (CIM) for research on the humanized monoclonal antibody Nimotuzumab.

January 11, 2023
14:44

The award was granted to a greatest scientific project, in this case Nimotuzumab that has been used for treating Covid-19 patients.

According to a CIM´s message on Twitter, “CITMA Special Award went to the title Repositioning of the Cuban humanized monoclonal antibody Nimotuzumab for treating Covid-19 patients”.

The CITMA and CIM strategic integration has made this scientific research a reality, the scientific institution recalled.

According to CIM´s Clinical Research Director Tania Crombet, Nimotuzumab was safe to be used for Covid-19 patients, proving an improved ventilatory function and a decreased inflammation markers.

After being applied to Covid-19 patients, results found evidence of a 80% of radiological recovery or stabilization of multifocal interstitial pneumonia on the seventh day of treatment.

Unlike other innovative molecules to be used for treating Covid-19, Nimotuzumab could have a key anti-inflammatory role, and also have an impact on reestablishing the coagulation disorder as well as preventing or reversing pulmonary fibrosis, Crombet pointed out.

pll/ro/crc